1don MSN
Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.
Soleno Therapeutics’ stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the ...
For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...
Early trials, according to The New York Times, have shown that people with obesity and knee osteoarthritis lost 28.7 percent of their body weight after taking the highest dose for nearly 70 weeks, ...
Armed with sophisticated chemistry and fresh approaches to drug design, researchers are closing in on innovative strategies ...
TAIPEI, March 5, 2026 /PRNewswire/ -- Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator ...
The discovery of new medicines often takes place in North America, Europe and Asia. So that's where the agenda tends to be ...
(Bloomberg) -- Amgen Inc. has acquired cancer drug developer Dark Blue Therapeutics Ltd. in a deal worth as much as $840 million, expanding its portfolio of oncology treatments. Based in the UK, ...
Shalini Arunogiri receives funding from the National Health and Medical Research Council. She has received speaker honoraria from Camurus and Indivior, and advisory board fees from Indivior and Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results